임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

60건 표시 (상위 60건)

3상모집 중단 (진행 중)· Hyperlipidemia
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
리드: 머크(MSD)
상세 →NCT07216482
3상모집 중단 (진행 중)· Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
협력: 머크(MSD)
상세 →NCT06726265
3상모집 중단 (진행 중)· Lung Cancer
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
리드: 머크(MSD)
상세 →NCT06698042
3상모집 중단 (진행 중)· HIV-1-infection
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
리드: 길리어드 · 협력: 머크(MSD)
상세 →NCT06630286
3상모집 중단 (진행 중)· HIV-1-Infection
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1
리드: 길리어드 · 협력: 머크(MSD)
상세 →NCT06630299
3상모집 중단 (진행 중)· Hypercholesterolemia
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
리드: 머크(MSD)
상세 →NCT06492291
3상모집 중단 (진행 중)· Cervical Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
리드: 머크(MSD)
상세 →NCT06459180
3상모집 중단 (진행 중)· Essential Thrombocythemia
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
리드: 머크(MSD)
상세 →NCT06456346
3상모집 중단 (진행 중)· Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
리드: 머크(MSD)
상세 →NCT06305754
3상모집 중단 (진행 중)· Gastroesophageal Cancer
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
리드: 머크(MSD)
상세 →NCT06356311
3상모집 중단 (진행 중)· Essential Thrombocythemia
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
리드: 머크(MSD)
상세 →NCT06079879
3상모집 중단 (진행 중)· Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
리드: 머크(MSD)
상세 →NCT06132958
3상모집 중단 (진행 중)· Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
리드: 머크(MSD)
상세 →NCT06074588
3상모집 중단 (진행 중)· HIV-1-infection
A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy
협력: 머크(MSD)
상세 →NCT05924438
3상모집 중단 (진행 중)· Ulcerative Colitis
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
리드: 머크(MSD)
상세 →NCT06052059
3상모집 중단 (진행 중)· Arteriosclerosis
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
리드: 머크(MSD)
상세 →NCT06008756
3상모집 중단 (진행 중)· Kidney Transplant; Complications
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients
협력: 머크(MSD)
상세 →NCT06001320
3상모집 중단 (진행 중)· Urothelial Carcinoma
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
리드: 화이자 · 협력: 머크(MSD)
상세 →NCT05911295
3상모집 중단 (진행 중)· Melanoma
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
리드: 머크(MSD) · 협력: 모더나
상세 →NCT05933577
3상모집 중단 (진행 중)· Metastatic Non-small Cell Lung Cancer
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
리드: 머크(MSD)
상세 →NCT06212752
3상모집 중단 (진행 중)· HIV Infection
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
리드: 머크(MSD)
상세 →NCT05766501
3상모집 중단 (진행 중)· Chronic Lymphocytic Leukemia
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
리드: 머크(MSD)
상세 →NCT05624554
3상모집 중단 (진행 중)· Recurrent Lung Non-Small Cell Carcinoma
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
협력: 일라이 릴리, 머크(MSD)
상세 →NCT05633602
3상모집 중단 (진행 중)· HIV-1 Infection
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
리드: 머크(MSD)
상세 →NCT05705349
3상모집 중단 (진행 중)· HIV-1 Infection
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
리드: 머크(MSD)
상세 →NCT05631093
3상모집 중단 (진행 중)· HIV-1 Infection
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
리드: 머크(MSD)
상세 →NCT05630755
3상모집 중단 (진행 중)· Metastatic Non-small Cell Lung Cancer
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
리드: 머크(MSD)
상세 →NCT05722015
3상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
리드: 머크(MSD) · 협력: 길리어드
상세 →NCT05609968
3상모집 중단 (진행 중)· Metastatic Non Small Cell Lung Cancer
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
협력: 아스트라제네카, 머크(MSD)
상세 →NCT05555732
3상모집 중단 (진행 중)· Carcinoma, Renal Cell
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
리드: 머크(MSD)
상세 →NCT05899049
3상모집 중단 (진행 중)· Triple Negative Breast Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
리드: 길리어드 · 협력: 머크(MSD)
상세 →NCT05382286
3상모집 중단 (진행 중)· Papillomavirus Infections
V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)
리드: 머크(MSD)
상세 →NCT05450705
3상모집 중단 (진행 중)· Nonsquamous Non-small Cell Lung Cancer
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
협력: 머크(MSD)
상세 →NCT05338970
3상모집 중단 (진행 중)· Metastatic Melanoma
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
협력: 머크(MSD)
상세 →NCT05155254
3상모집 중단 (진행 중)· Genital Warts
Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)
리드: 머크(MSD)
상세 →NCT05314023
3상모집 중단 (진행 중)· Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
리드: 머크(MSD)
상세 →NCT05298423
3상모집 중단 (진행 중)· Colorectal Neoplasms
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
리드: 머크(MSD)
상세 →NCT05239741
3상모집 중단 (진행 중)· Small Cell Lung Carcinoma
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
리드: 머크(MSD)
상세 →NCT05224141
3상모집 중단 (진행 중)· Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
리드: 머크(MSD)
상세 →NCT05239728
3상모집 중단 (진행 중)· Metastatic Non Small Cell Lung Cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
협력: 아스트라제네카, 머크(MSD)
상세 →NCT05215340
3상모집 중단 (진행 중)· Papillomavirus Infections
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
리드: 머크(MSD)
상세 →NCT05285826
3상모집 중단 (진행 중)· Endometrial Neoplasms
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
리드: 머크(MSD)
상세 →NCT05173987
3상모집 중단 (진행 중)· Ovarian Cancer
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
리드: 머크(MSD)
상세 →NCT05116189
3상모집 중단 (진행 중)· Neurofibromatosis 1
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
리드: 아스트라제네카 · 협력: 머크(MSD)
상세 →NCT04924608
3상모집 중단 (진행 중)· HIV-1 Infection
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
리드: 머크(MSD)
상세 →NCT04776252
3상모집 중단 (진행 중)· Non-Small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
리드: 머크(MSD)
상세 →NCT04956692
3상모집 중단 (진행 중)· Metastatic Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
리드: 머크(MSD)
상세 →NCT04949256
3상모집 중단 (진행 중)· Metastatic Castration-resistant Prostate Cancer
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
리드: 아스트라제네카 · 협력: 머크(MSD)
상세 →NCT05171816
3상모집 중단 (진행 중)· Breast Neoplasms
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
리드: 머크(MSD)
상세 →NCT04895358
3상모집 중단 (진행 중)· Bladder Cancer
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
리드: 머크(MSD)
상세 →NCT04700124
3상모집 중단 (진행 중)· Carcinoma, Renal Cell
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
리드: 머크(MSD)
상세 →NCT04736706
3상모집 중단 (진행 중)· Papillomavirus Infections
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
리드: 머크(MSD)
상세 →NCT04708041
3상모집 중단 (진행 중)· Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
리드: 머크(MSD)
상세 →NCT04586231
3상모집 중단 (진행 중)· HPV Positive Oropharyngeal Squamous Cell Carcinoma
Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV
협력: 머크(MSD)
상세 →NCT04255849
3상모집 중단 (진행 중)· Melanoma
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
리드: 화이자 · 협력: 머크(MSD)
상세 →NCT04657991
3상모집 중단 (진행 중)· Endometrial Neoplasms
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
리드: 머크(MSD)
상세 →NCT04634877
3상모집 중단 (진행 중)· Small Cell Lung Cancer
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
리드: 머크(MSD)
상세 →NCT04624204
3상모집 중단 (진행 중)· Peripheral Spondyloarthritis
Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade
협력: 머크(MSD)
상세 →NCT04435288
3상모집 중단 (진행 중)· Lung Neoplasms
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
리드: 머크(MSD)
상세 →NCT04380636
3상모집 중단 (진행 중)· Urinary Bladder Neoplasms
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
리드: 머크(MSD)
상세 →NCT04241185

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.